PLUVICTO contains the active ingredient lutetium (177Lu) vipivotide tetraxetan. PLUVICTO is used to treat prostate cancer in adults. For more
Pluvicto, was approved by the FDA. Pluvicto, lutetium Lu 177 vipivotide tetraxetan (formerly referred to as 177Lu-PSMA-617) is the first
Pluvicto is a radiopharmaceutical agent used to specifically treat advanced, metastatic castration-resistant prostate cancer.
Pluvicto is being reviewed by the Canadian Agency for Drugs and Technology in Health with Feb. 16, 2024, the deadline for stakeholder feedback. CADTH will recommend whether the drug should be publicly funded. Health Canada has approved Pluvicto and it can now be marketed.
What Is Pluvicto? Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
About Your Pluvicto Treatment This information will help you get ready for your Pluvicto treatment at MSK. Pluvicto is a type of radionuclide therapy called radioligand therapy (RLT). About Pluvicto Pluvicto is a targeted radioactive therapy. It has 2 main parts, targeted and radioactive. The targeted part finds and binds to cancer cells.
Some dosage forms listed on this page may not apply specifically to the brand name Pluvicto. Applies to lutetium lu 177 vipivotide tetraxetan: intravenous solution. Serious side effects of Pluvicto. Along with its needed effects, lutetium lu 177 vipivotide tetraxetan (the active ingredient contained in Pluvicto) may cause some unwanted effects
About Pluvicto. Pluvicto is a targeted radioactive therapy. It has 2 main parts, targeted and radioactive. The targeted part finds and binds to cancer cells.
About Pluvicto. Pluvicto, manufactured by Novartis, is a type of radiopharmaceutical medication used to treat prostate cancer that has spread to other parts of
Comments